lenograstim
Sign in to saveLenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
Research
420 papers- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.The Lancet. Oncology · 2012
- Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.Drugs · 2011
- Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.Drugs · 1995
- G-CSF: filgrastim, lenograstim and biosimilars.Expert opinion on biological therapy · 2014
- Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.Drugs · 2000
via PubMed
Wikidata facts
Show 1 more fact
- defined daily dose
- 0.35
Sources (2)
via Wikidata · CC0
~1 min read
Article
1 sectionsContents
- References
Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
== References ==
Available in 6 languages
via Wikidata sitelinks · CC0
Connections
interferon gamma
Entity
peginterferon alfa-2a
Entity
interferon type I
Entity
immunostimulant
Entity
colony-stimulating factor
Entity
momelotinib
Entity
medication
Entity
vaccine
Entity
digital object identifier
Entity
insulin
Entity
testosterone
Entity
vitamin D
Entity
Q180686
Entity
BCG vaccine
Entity
prolactin
Entity
interferon
Entity
CAS Registry Number
Entity
erythropoietin
Gene
heterocyclic compound
Entity
Q229883
Entity